Stock Scorecard
Stock Summary for Aquestive Therapeutics Inc (AQST) - $3.35 as of 6/18/2025 9:44:26 AM EST
Total Score
8 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AQST
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AQST
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AQST
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AQST
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AQST (27 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AQST
Financial Details for AQST
Company Overview |
|
|---|---|
| Ticker | AQST |
| Company Name | Aquestive Therapeutics Inc |
| Country | USA |
| Description | Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 3.35 |
| Price 4 Years Ago | 3.89 |
| Last Day Price Updated | 6/18/2025 9:44:26 AM EST |
| Last Day Volume | 1,671,856 |
| Average Daily Volume | 1,840,181 |
| 52-Week High | 5.80 |
| 52-Week Low | 2.12 |
| Last Price to 52 Week Low | 58.02% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.38 |
| Sector PE | 40.20 |
| 5-Year Average PE | -5.85 |
| Free Cash Flow Ratio | 4.86 |
| Industry Free Cash Flow Ratio | 17.66 |
| Sector Free Cash Flow Ratio | 31.91 |
| Current Ratio Most Recent Quarter | 4.87 |
| Total Cash Per Share | 0.69 |
| Book Value Per Share Most Recent Quarter | -0.61 |
| Price to Book Ratio | 0.00 |
| Industry Price to Book Ratio | 34.50 |
| Sector Price to Book Ratio | 30.01 |
| Price to Sales Ratio Twelve Trailing Months | 6.48 |
| Industry Price to Sales Ratio Twelve Trailing Months | 122.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 34.69 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 99,328,000 |
| Market Capitalization | 332,748,800 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -460.83% |
| Reported EPS 12 Trailing Months | -0.58 |
| Reported EPS Past Year | -0.22 |
| Reported EPS Prior Year | -0.49 |
| Net Income Twelve Trailing Months | -54,239,000 |
| Net Income Past Year | -44,137,000 |
| Net Income Prior Year | -7,870,000 |
| Quarterly Revenue Growth YOY | -27.70% |
| 5-Year Revenue Growth | 1.82% |
| Operating Margin Twelve Trailing Months | -222.10% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 68,657,000 |
| Total Cash Past Year | 71,546,000 |
| Total Cash Prior Year | 23,872,000 |
| Net Cash Position Most Recent Quarter | 34,911,000 |
| Net Cash Position Past Year | 39,046,000 |
| Long Term Debt Past Year | 32,500,000 |
| Long Term Debt Prior Year | 27,508,000 |
| Total Debt Most Recent Quarter | 33,746,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -60,156,000 |
| Total Stockholder Equity Prior Year | -106,487,000 |
| Total Stockholder Equity Most Recent Quarter | -60,930,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -49,040,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.49 |
| Free Cash Flow Past Year | -35,918,000 |
| Free Cash Flow Prior Year | -7,375,000 |
Options |
|
| Put/Call Ratio | 0.16 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.24 |
| MACD Signal | 0.18 |
| 20-Day Bollinger Lower Band | 2.20 |
| 20-Day Bollinger Middle Band | 2.91 |
| 20-Day Bollinger Upper Band | 3.61 |
| Beta | 1.93 |
| RSI | 65.41 |
| 50-Day SMA | 3.65 |
| 150-Day SMA | 2.50 |
| 200-Day SMA | 2.63 |
System |
|
| Modified | 6/17/2025 5:37:01 PM EST |